谷氨酸脱羧酶抗体对中国正常成年人糖尿病的预测价值：一项中国的回顾性队列研究。

Predictive Value of GAD Antibody for Diabetes in Normal Chinese Adults: A Retrospective Cohort Study in China.

作者信息

Li Jing, Lin Songbai, Deng Chuiwen, Xu Tengda

机构信息

Department of Health Management, Peking Union Medical College Hospital, Beijing, People's Republic of China.

Rheumatology and Immunology Department, Peking Union Medical College Hospital, Beijing, People's Republic of China.

出版信息

Diabetes Metab Syndr Obes. 2021 Mar 1;14:885-893. doi: 10.2147/DMSO.S298068. eCollection 2021.

DOI:10.2147/DMSO.S298068

PMID:33688223

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7935353/

Abstract

PURPOSE

To investigate the prevalence of GAD antibody (GADA) in the general adult population and to evaluate its predictive value for diabetes in China.

PATIENTS AND METHODS

We searched the PUMCH-HM database and identified 36,731 adult subjects with GADA test results from 2012 to 2015. We then established a retrospective cohort of 4835 nondiabetic subjects at baseline with complete annual health evaluation records through 2019. The median follow-up time was 4.8 (3.0-7.3) years.

RESULTS

The overall prevalence of GADA was 0.53% and was higher in diabetic subjects (1.25%) than in nondiabetic subjects (0.47%). We found a decrease in baseline body mass index (BMI) from the GADA- to GADA subgroups among baseline diabetic and prediabetic patients and also those who developed diabetes later in the cohort study. A total of 136 subjects (2.8%) developed diabetes after a median follow-up of 3.5 years. For GADA participants, BMI was not associated with the risk for diabetes. In the Cox regression model, the GADA and GADA exhibited 2.63-fold and 4.16-fold increased risk for diabetes, respectively. This increased risk for diabetes by GADA-positivity is only found in male adults (HR 4.55, 95% CI 2.25-9.23).

CONCLUSION

GADA has a low prevalence in China but is associated with a 2.63-4.16-fold increased risk for diabetes.

摘要

目的

调查中国普通成年人群中谷氨酸脱羧酶抗体（GADA）的患病率，并评估其对糖尿病的预测价值。

患者与方法

我们检索了北京协和医院健康管理数据库，确定了2012年至2015年有GADA检测结果的36731名成年受试者。然后，我们建立了一个回顾性队列，其中包括4835名基线时非糖尿病受试者，他们拥有截至2019年的完整年度健康评估记录。中位随访时间为4.8（3.0 - 7.3）年。

结果

GADA的总体患病率为0.53%，糖尿病患者中的患病率（1.25%）高于非糖尿病患者（0.47%）。我们发现，在基线糖尿病患者、糖尿病前期患者以及队列研究中后来患糖尿病的患者中，从GADA - 到GADA亚组，基线体重指数（BMI）有所下降。共有136名受试者（2.8%）在中位随访3.5年后患糖尿病。对于GADA参与者，BMI与糖尿病风险无关。在Cox回归模型中，GADA和GADA患糖尿病的风险分别增加了2.63倍和4.16倍。这种因GADA阳性导致的糖尿病风险增加仅在成年男性中发现（HR 4.55，95% CI 2.25 - 9.23）。